A Study to Evaluate the ePidemiology of anEmia Associated With chroNic Kidney Disease in Patients in Primary Care Using The Stockholm CREAtinine Measurement (SCREAM) Register

Astellas

Status: Completed

Conditions: Chronic Kidney Disease

Treatments: Other: Non-interventional

Study type: Observational

Funder types: Industry

Identifiers

NCT05015998

1517-MA-1569

Details and patient eligibility

About

The objectives of this analysis is to determine the incidence of anemia occurring in patients with chronic kidney disease (CKD) in primary care (i.e. prior to any eventual referral to nephrology care). This analysis also evaluates patient characteristics, anemia treatment and associated cardiovascular risk.

Full description

Data will be derived from the Stockholm CREATinine Measurement (SCREAM) cohort, a repository of laboratory data of individuals residing and accessing healthcare in the region of Stockholm and who underwent a creatinine assessment between 2012 - 2018.

Enrollment: 45,637 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient entered in SCREAM between 2012 and 2018
• With two consecutive plasma-creatinine test(s) indicating an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m^2
• With at least one eligible Hb after eGFR < 60 mL/min/1.73 m^2. The date of the first eligible Hb test is the study entry point/index date of the study.

Exclusion criteria

• Patient who has had a recent pregnancy or childbirth (issued diagnosis within 2 years prior to index date).
• Patient with ongoing/recent cancer (diagnosed within the previous 3 years), haematological diseases or leukaemia.
• Patient with chronic infections (hepatitis, tuberculosis, or human immunodeficiency virus [HIV]); note by definition chronic infections are chronic and look back period will be to 1997.
• Patients with anemia at baseline (index date), defined by an anemia diagnosis in the year prior, a baseline Hb value within the anemia range according to the WHO definition, or the presence of a recent dispensation of ESA or iron (up to six months prior).
• Patient referred to nephrologist within the previous 2 years from cohort entry/ index date.

Trial design

45,637 participants in 1 patient group

Non-dialysis dependent patients with CKD stage 3-5

Description:

A cohort of patients will be created from the Stockholm CREAtinine Measurement (SCREAM) cohort based on the eligibility criteria.

Treatment:

Other: Non-interventional